Put your patients in better control.

CGM First

Greater A1C Improvements

Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1

Reduction of Nighttime Hypoglycemia

Dexcom CGM has been shown to reduce median time spent in hypoglycemia by 79% (<60 mg/dL) at night.2


Driver of Benefits

The COMISAIR study demononstrates that Dexcom CGM use–not the insulin delivery method–drives A1C reduction. Both MDI patients and those on pump therapy experience significant glycemic benefits when their insulin regimens are augmented by CGM use.1

COMISAIR Study Shows CGM—Not the Delivery System—Drives A1C Reduction<sup>1</sup>

Medicare Coverage for CGM

Medicare now provides coverage for therapeutic CGM systems (those indicated for use in making diabetes treatment decisions). The Dexcom G5® Mobile CGM System is the first and only mobile-enabled CGM system covered as a Medicare benefit.

Information for Patients


Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.


Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.